These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 2247526)

  • 1. [Factors affecting the disease course in multiple sclerosis].
    Lakner K
    Psychiatr Neurol Med Psychol (Leipz); 1990 Aug; 42(8):467-72. PubMed ID: 2247526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.
    Glad SB; Nyland HI; Aarseth JH; Riise T; Myhr KM
    Mult Scler; 2009 Aug; 15(8):942-50. PubMed ID: 19570821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Forms of disease progression and prognostic factors in multiple sclerosis].
    Meyer-Rienecker HJ; Hitzschke B; Buddenhagen F; Lakner K
    Psychiatr Neurol Med Psychol (Leipz); 1988 Oct; 40(10):588-97. PubMed ID: 3237865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Will Rogers phenomenon in multiple sclerosis.
    Sormani MP; Tintorè M; Rovaris M; Rovira A; Vidal X; Bruzzi P; Filippi M; Montalban X
    Ann Neurol; 2008 Oct; 64(4):428-33. PubMed ID: 18688811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic and acute pain syndromes in patients with multiple sclerosis.
    Indaco A; Iachetta C; Nappi C; Socci L; Carrieri PB
    Acta Neurol (Napoli); 1994 Jun; 16(3):97-102. PubMed ID: 7992668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural history and treatment of multiple sclerosis.
    Weinshenker BG; Sibley WA
    Curr Opin Neurol Neurosurg; 1992 Apr; 5(2):203-11. PubMed ID: 1377973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple sclerosis: epidemiology, genetics, classification, natural history, and clinical outcome measures.
    Wingerchuk DM; Weinshenker BG
    Neuroimaging Clin N Am; 2000 Nov; 10(4):611-24 ,vii. PubMed ID: 11359715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the natural history and prognostic features of early onset and adult onset multiple sclerosis in Jordanian population.
    El-Salem K; Khader Y
    Clin Neurol Neurosurg; 2007 Jan; 109(1):32-7. PubMed ID: 16870328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease.
    Siva A; Saip S; Altintas A; Jacob A; Keegan BM; Kantarci OH
    Mult Scler; 2009 Aug; 15(8):918-27. PubMed ID: 19667020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rehabilitation management in neurologic follow-up of the multiple sclerosis patient].
    Borgel F
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1135-8. PubMed ID: 11787346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The significance of oligoclonal bands in multiple sclerosis: relevance of demographic and clinical features, and immunogenetic backgrounds.
    Idiman E; Ozakbas S; Dogan Y; Kosehasanogullari G
    J Neuroimmunol; 2009 Jul; 212(1-2):121-4. PubMed ID: 19457560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinical longitudinal study of multiple sclerosis in Cantabria, Spain.
    Morís G; Berciano J; Miró J
    Neurologia; 2003 Dec; 18(10):723-30. PubMed ID: 14648348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The multiple sclerosis trait: a disease waiting to happen?
    Sadovnick AD
    Clin Neurol Neurosurg; 2004 Jun; 106(3):172-4. PubMed ID: 15177765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution and severity markers in 233 MS patients.
    Bernardi S; Buttinelli C; Grasso MG; Millefiorini E; Pace A; Prencipe M; Fieschi C
    Riv Neurol; 1987; 57(3):197-200. PubMed ID: 3672012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
    Baier ML; Cutter GR; Rudick RA; Miller D; Cohen JA; Weinstock-Guttman B; Mass M; Balcer LJ
    Neurology; 2005 Mar; 64(6):992-5. PubMed ID: 15781814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Course of illness and prognosis of multiple sclerosis. 2: Predictive value of clinical and paraclinical factors].
    Flachenecker P; Hartung HP
    Nervenarzt; 1996 Jun; 67(6):444-51. PubMed ID: 8767198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
    Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P
    Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of depression and disability on quality of life in Iranian patients with multiple sclerosis.
    Ayatollahi P; Nafissi S; Eshraghian MR; Kaviani H; Tarazi A
    Mult Scler; 2007 Mar; 13(2):275-7. PubMed ID: 17439899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.